Navigation Links
Wistar researchers: Direct proof of how T cells stay in 'standby' mode
Date:5/5/2011

For much of the time our T cellsthe white blood cells that act as the police of the immune systemare in what immunologists call a "quiescent state," a sort of standby mode. For years, scientists have wondered if quiescence occurred by default or whether T cells need to work at remaining silent. Now, researchers at The Wistar Institute provide the first direct proof that a protein, called Foxp1, actively maintains this state of quiescence in T cells until the cells are called upon by other parts of the immune system.

Their findings, which appear online through Nature Immunology ahead of print publication, could one day enable researchers to activate T cells to fight diseases such as cancer, which can go undetected or unrecognized by the immune system. In fact, the researchers report that knocking out the Foxp1 protein in mice activates T cells, allowing the cells to work in their policing function.

"T cell quiescence has been a big mystery in immunology with some obvious and profound implications for treating illness by manipulating the immune system," said Hui Hu, Ph.D., senior author of the study and assistant professor in the Immunology Program at The Wistar Institute. "We believe we have provided evidence that quiescence is not just a passive, default state, and we are now beginning to understand the molecular mechanisms by which it happens."

Mature T cells are generated in the thymus, an organ located in front of heart, and then exit into the periphery. There, these T cells are in a "nave," quiescent state, awaiting orders to act. Activation primarily requires antigen-presenting cell, which offers up an antigen (a particle that the immune system recognizes as "foreign") to the T cell Receptor (TCR). This activated TCR, then, gives the T cell specificity.

Foxp1 is a transcription factor, a protein that binds to DNA and causes the cell to reador transcribespecific genes. The Hu laboratory had previously shown that the Foxp1 protein is important for T cell development in the thymus. In order to understand how Foxp1 operates in mature T cells, the researchers used an inducible deletion model system where they could choose to delete the gene's activity after the cells have already matured.

In studying these Foxp1-less T cells, Hu and his colleagues discovered that naive T cells without Foxp1 become activated and proliferate in response to the protein IL-7, without antigen triggers. Hu and his colleagues discovered that Foxp1 represses the expression of the receptor for IL-7, and some other key signaling, in regulating T cell quiescence.

Foxp1, the researchers found, is similar to a related transcription factor, called Foxo1, a well-studied protein with numerous roles in both cancer and aging. In T cells, Foxo1 helps induce the creation of IL-7 receptors, which allows the T cell to receive the IL-7 signal. Foxp1, they found, directly competed with Foxo1's DNA binding spot, thereby limiting the number of IL-7 receptors each T cell has. Such inter-protein competition helps maintain a balanced state within the cell, Hu says.

Among their key findings, Hu believes, is that removing Foxp1 can cause T cells to proliferate without triggering the TCR. "Antigenic specificity is the key characteristic of T cells and our adaptive immunity," Hu. Said. "We never thought a naive T cell could be activated without stimulation through the T cell receptor."

"It came as such a surprise that the deletion of Foxp1, basically the removal of an essential negative regulation, could lead naive T cells to bypass overt antigen recognition and become activated with effector functions," Hu.

According to Hu, his laboratory, in collaboration with fellow laboratories at Wistar, are now investigating the possibility of knocking out Foxp1 to stimulate T cells in the tumor microenvironment.

"Many cancers cause local T cells to become effectively unresponsive or 'quiescent,' thereby allowing tumors to grow unimpeded by the immune system," Hu said. "We suspect that the tumor cells may 'hijack' the cell-intrinsic quiescence mechanism. In addition, many tumor antigens are poorly immunogenic. By manipulating Foxp1 expression, we may bypass the poor tumor antigen stimulation and restore T cell activation within tumors in the hopes that the immune system will clear away cancerous cells."


'/>"/>

Contact: Greg Lester
glester@wistar.org
215-898-3943
The Wistar Institute
Source:Eurekalert

Related medicine news :

1. Wistar researchers follow a path to a potential therapy for NF2, a rare tumor disorder
2. Wistar researchers discover new class of objects encoded within the genome
3. Wistar scientists explain the persistence of melanoma through dynamic stemness
4. Researchers: Sexually active teens need confidential health care
5. Researchers: Elderly patients 4 times more likely to die from treatment complications
6. Researchers: Pay more attention to epilepsy
7. Ben-Gurion U. researchers: High resistance rates among acute otitis media pathogens in children
8. IU researchers: Chemotherapy alters brain tissue in breast cancer patients
9. New direction for epilepsy treatment
10. Center director says FDA hitting milestones in tobacco law
11. How we manage water resources has a direct impact on our health, says Canada Research Chair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... York, NY & Greenwich, CT (PRWEB) , ... March 01, 2017 ... ... many runners, especially in the winter months when people don’t want to stop training ... the knees – and setting the treadmill to a small incline can help protect ...
(Date:3/1/2017)... ... , ... “McFarnia”: a suspenseful tale of a father who vanishes without a ... disappearance. “McFarnia” is the creation of published author Tony Pierzchala, a former Army man, ... a Chaplain with Transport for Christ at a truck stop in the Greensboro area. ...
(Date:3/1/2017)... ... ... of Love”: a tale of young love and war. ““Letter of Love”” is the ... Salvador, wife, mother, and co-founder of a Christian College. , “I turned to ... poor communities, and I study psychology. I lived the civil war. ” --Maria Teresa ...
(Date:3/1/2017)... ... , ... “The Affair is Over Now Go Live Your Life Abundantly”: a ... affair. “The Affair is Over Now Go Live Your Life Abundantly” is the creation ... dedicated her professional life to teaching and writing about marriage and family life in ...
(Date:2/28/2017)... ... , ... Answering strong demand for its medical device software design and development ... in the Soma neighborhood in San Francisco on March 1, 2017. The opening also ... systems architecture subject matter experts. , Orthogonal serves a sizeable clientele in the Bay ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... DIEGO , March 1, 2017  Aethlon ... European Patent Office has granted European Patent Number ... In recent years, exosomes have emerged ... a wide range of disease conditions, including cancer, ... (CTE).  This granted European Patent is an important ...
(Date:3/1/2017)... 1, 2017  Numotion, the nation,s leading provider of ... Tek RMD ("robotic mobilization device") by Matia Robotics in ... is a motorized standing movement device that offers the ... to complete everyday activities from a standing position. Unlike ... RMD unassisted. Numotion is the exclusive distributor of the ...
(Date:3/1/2017)... ... and Markets has announced the addition of the "Global Infertility ... The Global Infertility Therapy Partnering Terms and Agreements since 2010 ... into by the world,s leading healthcare companies. The report ... discovery or development stage whereby the licensee obtains a right or ...
Breaking Medicine Technology: